European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells·    ...

The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans ...

Olon Group, a leading global pharmaceutical CDMO, announces the appointment of Jérôme Bédier as CEO of its French entities and Andrea Conforto as M&S VP CDMO of Olon Biotech, the division dedicated to ...

The Digital Poverty Alliance (DPA) has launched an inquiry into digital inclusion in the healthcare sector amid government announcements to allocate billions to digital transformation. At a time where ...

NCIMB Limited ("NCIMB"), a leading microbiology services provider and owner of the UK’s largest industrial, food and marine bacterial culture collection, has secured a £1.7m investment from the ...

RetinAI US Inc. (RetinAI) and      Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has ...

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial ...

A recent video produced by Vapourtec highlights the patented automatic Variable Bed Flow Reactor (VBFR) demonstrating fully automated solid phase peptide synthesis (SPPS).The process begins with ...

Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors, is proud to announce the ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...